Department of Chemistry , University of Waterloo , 200 University Avenue West , Waterloo , Ontario N2L 3G1 , Canada.
Department of Food Science and Technology , The Ohio State University , 2015 Fyffe Court , Columbus , Ohio 43210 , United States.
J Org Chem. 2019 May 3;84(9):5339-5347. doi: 10.1021/acs.joc.9b00364. Epub 2019 Apr 10.
Paenibacterin is a recently discovered cyclic lipodepsipeptide antibiotic produced by the soil bacterium Paenibacillus thiaminolyticus. It is produced as a mixture of three compounds with isomeric 15-carbon acyl lipids, designated P-A1 (linear lipid), P-A2 (anteiso lipid), and P-A3 (iso lipid). Here, we report the total synthesis of P-A1 and P-A2, as well as two analogues of P-A1 in which the threonine residue in P-A1 was replaced with l-2,3-diaminopropionic acid (P-A1-Dapa) and (2 S,3 R)-2,3-diaminobutyric acid (P-A1-Daba), converting the ring-closing ester bond to an amide bond. Solid phase peptide chemistry was used to prepare branched precursors which were cyclized off-resin to obtain the target peptides in good to excellent overall yields. The use of a pseudoproline dipeptide building block was found to be important for obtaining good yields. The antibacterial activity of the peptides was determined against Escherichia coli K-12 (G) and Bacillus subtilis 1046 (G). The minimum inhibitory concentrations of P-A1 and P-A2 were the same despite the variation in the structure of the acyl tail. Replacing the ring-closing ester bond with an amide bond had little or no effect on activity. The synthetic routes developed here should prove to be useful for creating new antibiotics based on the structure of paenibacterin.
类芽孢杆菌素是一种最近发现的由土壤细菌解硫胺素短小芽孢杆菌产生的环状脂肽抗生素。它是由三种具有异构 15 碳酰基脂的化合物组成的混合物,分别命名为 P-A1(线性脂)、P-A2(anteiso 脂)和 P-A3(iso 脂)。在这里,我们报告了 P-A1 和 P-A2 的全合成,以及 P-A1 的两种类似物的合成,其中 P-A1 中的苏氨酸残基被 l-2,3-二氨基丙酸(P-A1-Dapa)和(2S,3R)-2,3-二氨基丁酸(P-A1-Daba)取代,将环化酯键转化为酰胺键。固相肽化学被用来制备支化前体,这些前体在树脂外环化得到目标肽,总收率良好到优秀。发现使用假脯氨酸二肽砌块对于获得良好的收率非常重要。肽的抗菌活性针对大肠杆菌 K-12(G)和枯草芽孢杆菌 1046(G)进行了测定。尽管酰基尾部结构有所不同,但 P-A1 和 P-A2 的最小抑菌浓度相同。用酰胺键替代环化酯键对活性几乎没有影响或没有影响。这里开发的合成路线应该有助于基于类芽孢杆菌素的结构创造新的抗生素。